Human Chorionic Gonadotropin Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Human Chorionic Gonadotropin Market is Segmented by Product (Naturally Extracted and Recombinant), Application (Male Hypogonadism, Female Infertility Treatment, Oligospermic Treatment, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market size and forecast in value (in USD million) for the above segments.

Human Chorionic Gonadotropin Market Size

Human Chorionic Gonadotropin Market Summary
share button
Study Period 2019-2027
Base Year For Estimation 2022
CAGR 7.60 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Human Chorionic Gonadotropin Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Human Chorionic Gonadotropin Market Analysis

Over the next few years, the human chorionic gonadotropin market is expected to register a CAGR of about 7.6%.

Due to COVID-19 restrictions worldwide, foot traffic in hospitals and clinics decreased significantly, negatively impacting the growth of the human chorionic gonadotropin market. For instance, according to the research study published by Frontiers Media S.A. in April 2022, many infertile patients decided not to request assisted reproductive technology (ART) treatments due to the pandemic. During the pandemic, there was a decline in the number of concluded ART cycles as compared to the preceding year (749 vs. 844 cycles). This decline, despite the unchanged availability of ART services, is attributed to many factors: the local restrictions and the fear of SARS-Cov-2 infection and potential adverse obstetric outcomes did not encourage physicians and patients to engage in ART. Although, with the ongoing vaccinations and decreasing cases of COVID-19, the market is expected to regain normalcy over the coming years.

The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman's chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.

In addition, increasing awareness about HCG among healthcare professionals and patients, coupled with the new product launches, is anticipated to boost the market's growth over the forecast period. Human chorionic gonadotropin is used as a marker in cancer, including choriocarcinoma, seminoma, and germ cell tumors, which may augment the market's growth over the coming years with the increasing cases of cancer. For example, as per the article published in January 2020 by David G. Grenache, HCG was initially developed as a test for pregnancy. But HCG is now commonly used to test women who might have an ectopic pregnancy, along with other biomarkers, to look for fetal aneuploidies and as a tumor marker for a wide range of neoplasms.

Therefore, the factors mentioned above are attributed collectively to the studied market's growth over the forecast period. However, the availability of substitutes is expected to hinder market growth over the forecast period.

Human Chorionic Gonadotropin Market Trends

This section covers the major market trends shaping the Human Chorionic Gonadotropin Market according to our research experts:

Female Infertility Treatment Segment is Anticipated to Grow at a Significant Rate Over the Forecast Period

Infertility is defined as the inability of the couple to get pregnant or the inability of the woman to carry a pregnancy to term. As the human chorionic gonadotropin (HCG) hormone plays a vital role after the formation of the embryo during pregnancy, the use of HCG in infertility treatment has gained traction in both men and women. Infertility in females can be caused by different reasons. According to the World Health Organization, the primary factors include tubal disorders like a blocked fallopian tube, uterine diseases, polycystic ovarian syndrome (PCOS), other follicular disorders, and endocrine system disorders. With the growing burden of infertility in females worldwide, the demand for effective treatment is increasing, which is expected to drive the segment's growth over the forecast period. According to a research study published by the National Library of Medicine in December 2021, the overall prevalence of infertility was 24.58%, with 6.54% of women experiencing primary infertility and 18.04% experiencing secondary infertility.Thus, due to the high prevalence of infertility among women, the use of HCG is expected to increase over the coming years, thus driving the market's growth.

Further, the recombinant human chorionic gonadotropin products are anticipated to have significant growth due to the availability of different strengths and dosages for the individualization of therapy. Demand for naturally extracted HCG hormone products is also going up because new products are coming out and people are using them more. This could help the segment grow over the next few years.

Countries with the Lowest Birth Rate per 1000 People, 2021

North America is Expected to Dominate the Human Chorionic Gonadotropin Market Over the Forecast Period

North America is anticipated to have significant market growth over the forecast period. The increase may be attributed to well-established healthcare infrastructure, favorable reimbursement policies, and the growing burden of infertility in the region.

According to the March 2022 update of the Centers for Disease Control and Prevention (CDC), in the United States, among heterosexual women aged 15-49 years with no prior births, about 1 in 5 (19%) are unable to get pregnant after one year of trying (infertility). Also, about 1 in 4 (26%) women in this group have difficulty getting pregnant or carrying a pregnancy to term (impaired fecundity). Furthermore, according to the WHO 2022 update, 15% of reproductive-aged couples worldwide are affected by infertility. This data shows a prevalence of infertility and impaired fecundity in the region, which may drive the demand for HCG for infertility treatment in the country, thus boosting the market's growth in North America.

With rising awareness about infertility and its associated factors, the growing adoption of assisted reproductive technology (ART), and the development and acquisition of market players, the human chorionic gonadotropin (HCG) market is expected to grow further during the forecast period. For instance, in November 2021, InsurMedix, an AI-powered insurance platform, closed a USD 65 million funding round to provide coverage for fertility treatments. The platform, launched in the United States in early 2022, offers medical insurance for reproductive treatments and offers coverage for complementary and alternative medicine as well as medical tourism for care received outside of the country. As a result, these changes are likely to help the market grow in the region over the next few years.

Human Chorionic Gonadotropin Market - Growth Rate by Region

Human Chorionic Gonadotropin Industry Overview

The human chorionic gonadotropin market is moderate due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of international and local companies that hold market shares and are well known, including Merck KGaA, Fresenius SE & Co. KGaA, Lupin Limited, Sanzyme, and Merck & Co. Inc., among others.

Human Chorionic Gonadotropin Market Leaders

  1. Sanzyme

  2. Merck & Co. Inc.

  3. Ferring BV

  4. Fresenius Kabi AG

  5. Sun Pharmaceutical Industries Ltd

*Disclaimer: Major Players sorted in no particular order


Human Chorionic Gonadotropin Market News

  • June 2022: Inception Fertility expanded its ecosystem to include the launch of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that offers a unique experience for fertility providers and patients.
  • September 2021: Merck acquired Acceleron for USD 180 per share in cash for an approximate total equity value of USD 11.5 billion.

Human Chorionic Gonadotropin Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 The Increasing Prevalence of Infertility and Hypogonadism

      2. 4.2.2 Changing Lifestyle and Awareness Regarding the Treatment of Infertility

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Substitutes

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product

      1. 5.1.1 Natural Extracted

      2. 5.1.2 Recombinant

    2. 5.2 By Applications

      1. 5.2.1 Male Hypogonadism

      2. 5.2.2 Female Infertility Treatment

      3. 5.2.3 Oligospermic Treatment

      4. 5.2.4 Other Applications

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Sanzyme

      2. 6.1.2 Merck & Co. Inc.

      3. 6.1.3 Ferring BV

      4. 6.1.4 Fresenius Kabi AG

      5. 6.1.5 Sun Pharmaceutical Industries Ltd

      6. 6.1.6 Medix Biochemica (Lee BioSolutions Inc.)

      7. 6.1.7 Scripps Laboratories

      8. 6.1.8 Prospec-Tany Technogene Ltd

      9. 6.1.9 Biocare Medical LLC

      10. 6.1.10 Kamiya Biomedical Company

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Human Chorionic Gonadotropin Industry Segmentation

As per the scope of the report, the human chorionic gonadotropin hormone is a placental hormone secreted by syncytiotrophoblast cells during pregnancy. These hormones stimulate the corpus luteum to produce progesterone. The naturally extracted or recombinant human chorionic gonadotropin hormones are used in the treatment of infertility, male hypogonadism, and many other conditions. The human chorionic gonadotropin market is segmented by product (naturally extracted and recombinant), application (male hypogonadism, female infertility treatment, oligospermia treatment, and other applications), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Natural Extracted
By Applications
Male Hypogonadism
Female Infertility Treatment
Oligospermic Treatment
Other Applications
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Human Chorionic Gonadotropin Market Research FAQs

The Human Chorionic Gonadotropin Market is projected to register a CAGR of 7.6% during the forecast period (2023-2027).

Sanzyme, Merck & Co. Inc., Ferring BV, Fresenius Kabi AG and Sun Pharmaceutical Industries Ltd are the major companies operating in the Human Chorionic Gonadotropin Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2027).

In 2023, the North America accounts for the largest market share in the Human Chorionic Gonadotropin Market.

Human Chorionic Gonadotropin Industry Report

Statistics for the 2023 Human Chorionic Gonadotropin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Human Chorionic Gonadotropin analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!